1418 related articles for article (PubMed ID: 29339539)
1. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
Janse van Rensburg HJ; Azad T; Ling M; Hao Y; Snetsinger B; Khanal P; Minassian LM; Graham CH; Rauh MJ; Yang X
Cancer Res; 2018 Mar; 78(6):1457-1470. PubMed ID: 29339539
[TBL] [Abstract][Full Text] [Related]
2. Transcriptional co-repressor function of the hippo pathway transducers YAP and TAZ.
Kim M; Kim T; Johnson RL; Lim DS
Cell Rep; 2015 Apr; 11(2):270-82. PubMed ID: 25843714
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
Chen M; Wang M; Xu S; Guo X; Jiang J
Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
[TBL] [Abstract][Full Text] [Related]
4. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma.
Lee BS; Park DI; Lee DH; Lee JE; Yeo MK; Park YH; Lim DS; Choi W; Lee DH; Yoo G; Kim HB; Kang D; Moon JY; Jung SS; Kim JO; Cho SY; Park HS; Chung C
Biochem Biophys Res Commun; 2017 Sep; 491(2):493-499. PubMed ID: 28684311
[TBL] [Abstract][Full Text] [Related]
5. Regulation of Hippo pathway transcription factor TEAD by p38 MAPK-induced cytoplasmic translocation.
Lin KC; Moroishi T; Meng Z; Jeong HS; Plouffe SW; Sekido Y; Han J; Park HW; Guan KL
Nat Cell Biol; 2017 Jul; 19(8):996-1002. PubMed ID: 28752853
[TBL] [Abstract][Full Text] [Related]
6. Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells.
Feng J; Yang H; Zhang Y; Wei H; Zhu Z; Zhu B; Yang M; Cao W; Wang L; Wu Z
Oncogene; 2017 Oct; 36(42):5829-5839. PubMed ID: 28604752
[TBL] [Abstract][Full Text] [Related]
7. Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway.
Jang JW; Kim MK; Bae SC
Small GTPases; 2020 Jul; 11(4):280-288. PubMed ID: 29457552
[TBL] [Abstract][Full Text] [Related]
8. A kinome-wide screen using a NanoLuc LATS luminescent biosensor identifies ALK as a novel regulator of the Hippo pathway in tumorigenesis and immune evasion.
Nouri K; Azad T; Lightbody E; Khanal P; Nicol CJ; Yang X
FASEB J; 2019 Nov; 33(11):12487-12499. PubMed ID: 31431076
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of DCLK1 down-regulates PD-L1 expression through Hippo pathway in human pancreatic cancer.
Yan R; Li J; Zhou Y; Yao L; Sun R; Xu Y; Ge Y; An G
Life Sci; 2020 Jan; 241():117150. PubMed ID: 31837335
[TBL] [Abstract][Full Text] [Related]
10. Hippo Component TAZ Functions as a Co-repressor and Negatively Regulates ΔNp63 Transcription through TEA Domain (TEAD) Transcription Factor.
Valencia-Sama I; Zhao Y; Lai D; Janse van Rensburg HJ; Hao Y; Yang X
J Biol Chem; 2015 Jul; 290(27):16906-17. PubMed ID: 25995450
[TBL] [Abstract][Full Text] [Related]
11. Sphingosylphosphorylcholine regulates the Hippo signaling pathway in a dual manner.
Kemppainen K; Wentus N; Lassila T; Laiho A; Törnquist K
Cell Signal; 2016 Dec; 28(12):1894-1903. PubMed ID: 27634386
[TBL] [Abstract][Full Text] [Related]
12. Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS Kinase and Core Components of the Hippo Pathway.
Toloczko A; Guo F; Yuen HF; Wen Q; Wood SA; Ong YS; Chan PY; Shaik AA; Gunaratne J; Dunne MJ; Hong W; Chan SW
Cancer Res; 2017 Sep; 77(18):4921-4933. PubMed ID: 28720576
[TBL] [Abstract][Full Text] [Related]
13. Nuclear phosphoinositide signaling promotes YAP/TAZ-TEAD transcriptional activity in breast cancer.
Jung O; Baek MJ; Wooldrik C; Johnson KR; Fisher KW; Lou J; Ricks TJ; Wen T; Best MD; Cryns VL; Anderson RA; Choi S
EMBO J; 2024 May; 43(9):1740-1769. PubMed ID: 38565949
[TBL] [Abstract][Full Text] [Related]
14. The Hippo pathway effector proteins YAP and TAZ have both distinct and overlapping functions in the cell.
Plouffe SW; Lin KC; Moore JL; Tan FE; Ma S; Ye Z; Qiu Y; Ren B; Guan KL
J Biol Chem; 2018 Jul; 293(28):11230-11240. PubMed ID: 29802201
[TBL] [Abstract][Full Text] [Related]
15. A conserved MST1/2-YAP axis mediates Hippo signaling during lung growth.
Lin C; Yao E; Chuang PT
Dev Biol; 2015 Jul; 403(1):101-13. PubMed ID: 25912685
[TBL] [Abstract][Full Text] [Related]
16. YAP/TAZ Initiates Gastric Tumorigenesis via Upregulation of MYC.
Choi W; Kim J; Park J; Lee DH; Hwang D; Kim JH; Ashktorab H; Smoot D; Kim SY; Choi C; Koh GY; Lim DS
Cancer Res; 2018 Jun; 78(12):3306-3320. PubMed ID: 29669762
[TBL] [Abstract][Full Text] [Related]
17. YAP/TAZ for cancer therapy: opportunities and challenges (review).
Guo L; Teng L
Int J Oncol; 2015 Apr; 46(4):1444-52. PubMed ID: 25652178
[TBL] [Abstract][Full Text] [Related]
18. Arhgef7 promotes activation of the Hippo pathway core kinase Lats.
Heidary Arash E; Song KM; Song S; Shiban A; Attisano L
EMBO J; 2014 Dec; 33(24):2997-3011. PubMed ID: 25425573
[TBL] [Abstract][Full Text] [Related]
19. The Hippo Pathway Prevents YAP/TAZ-Driven Hypertranscription and Controls Neural Progenitor Number.
Lavado A; Park JY; Paré J; Finkelstein D; Pan H; Xu B; Fan Y; Kumar RP; Neale G; Kwak YD; McKinnon PJ; Johnson RL; Cao X
Dev Cell; 2018 Dec; 47(5):576-591.e8. PubMed ID: 30523785
[TBL] [Abstract][Full Text] [Related]
20. The nonreceptor tyrosine kinase c-Src attenuates SCF(β-TrCP) E3-ligase activity abrogating Taz proteasomal degradation.
Shanzer M; Adler J; Ricardo-Lax I; Reuven N; Shaul Y
Proc Natl Acad Sci U S A; 2017 Feb; 114(7):1678-1683. PubMed ID: 28154141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
